Infinata’s BioPharm Insight Database Leveraged by Canadian National Prescription Drug Utilization Information System
Norwood, MA (PRWEB) July 25, 2013 -- The Canadian Patented Medicine Prices Review Board (PMPRB) reported that BioPharm Insight’s database was the main source of information for Canada’s National Prescription Drug Utilization Information System (NPDUIS). BioPharm Insight is Infinata’s flagship intelligence solution for the global healthcare community.
The PMPRB is an independent quasi-judicial body established by the Canadian Parliament. The PMPRB ensures that prices at which patentees sell their patented medicines in Canada are not excessive and it reports on pharmaceutical trends of all medicines and R&D spending by patentees. The PMPRB reports annually to Parliament, through the Minister of Health, on its activities, on pharmaceutical trends relating to all medicines, and on R&D spending by patentees.
The NPDUIS provides critical analyses of drug price, utilization, and cost trends in Canada to support drug plan policy decision-making for participating federal, provincial, and territorial governments.
According to the PMPRB April 2013 New Drug Pipeline Monitor report, “The main source of information for the NDPM is the BioPharm Insight database, which tracks drugs from pre-clinical discovery through clinical trials to market launch and subsequent sales. The database is a comprehensive resource on investigational drugs and, at any one time, may contain more than 21,000 drugs. The database search capabilities allow drugs to be selected under various fields, including phase of development, therapeutic area, indication, drug mechanism, orphan drug, fast track and molecule type.” See the report here.
Ruth McHenry, Managing Director of Infinata, said, “We’re honored that the Canadian health care system leverages BioPharm Insight’s database. With our Clear Quality initiative which has more than 250 individual quality checks and processes, we strive to ensure every one of our hundreds of thousands of data points is as current and accurate as possible for data integrity, consistency and accessibility.”
Learn how BioPharm Insight can help you find new business opportunities. Start your free trial today. Gain access to all the data, analytics and intelligence mentioned in this news release.
About BioPharm Insight
BioPharm Insight is the definitive guide to the global biopharma community. BioPharm Insight provides subscribers with an information edge by combining the most comprehensive real-time database of companies, drugs, contacts, M&A and licensing deals, forecasts and clinical trial data with proprietary forward-looking intelligence uncovered by an independent team of investigative journalists months or even years before it breaks in mainstream media. To learn more, visit http://www.biopharminsight.com. Follow BioPharm Insight on LinkedIn and Twitter.
About Infinata, Inc.
Infinata provides personalized technology solutions to turn information into insight. Services include a comprehensive BioPharm Solutions Suite, unique Wealth Prospecting tools and innovative Custom Data Services. Infinata is a part of Mergermarket, a Financial Times Group company and a division of Pearson plc. To learn more, visit http://www.infinata.com.
Contact: Holly Burke, hburke(at)infinata(dot)com, 781-619-0131
Holly Burke, Infinata, http://www.infinata.com, 781.619.0131, [email protected]
Share this article